News
-
-
PRESS RELEASE
Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on APONTIS PHARMA AG with a Buy rating and EUR 17.00 price target. Apontis focuses on cardiovascular and respiratory drugs in Germany, led by CEO Wohlschlegel to drive efficiency and growth -
-
PRESS RELEASE
EV Nickel Provides Update on 2024 Exploration Plan - Initiates Diamond Drill Program on High Grade Target
EV Nickel Inc. (TSX-V:EVNI) provides update on 2024 Exploration Plan, diamond drilling on Langmuir #2 high priority nickel target. Expanding activities on CarLang resource, drilling high-grade targets, advancing clean metal bioleaching program -
-
PRESS RELEASE
EV Nickel Surface Sample Program Identifies Significant Extension Of Large-Scale Nickel Mineralization Along The Carlang Trend
EV Nickel Inc. announces positive assay results from 148 surface samples at the CarLang Trend in its Shaw Dome Project. Potential for large contiguous nickel mineralization. Expansion of sampling program planned -
-
PRESS RELEASE
APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management
APONTIS PHARMA appoints renowned industry expert Mila Brückel as Head of Supply Chain, gearing organization towards growth and internationalization -
-
PRESS RELEASE
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed
APONTIS PHARMA reports growth in revenue of Single Pill combinations and positive net result in Q1 2024, confirming forecast for full-year 2024. Improved EBITDA and new sales model aims to increase revenue further